Business Context and Reporting Period
Company: PharmAthene, Inc. (Note: Request metadata listed "Altimmune, Inc.", but the filing text identifies the registrant as PharmAthene, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: PharmAthene is a biodefense company developing medical countermeasures against biological and chemical weapons. Its lead product candidates include SparVax™ (anthrax vaccine), Valortim® (anthrax monoclonal antibody), and rBChE (nerve agent countermeasure). The company relies heavily on U.S. government contracts and grants for revenue.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Revenue | $21.0 million | $27.5 million |
| Net Loss | $(34.8) million | $(32.3) million |
| Research & Development Expenses | $20.9 million | $30.2 million |
| General & Administrative Expenses | $18.0 million | $22.4 million |
| Cash and Cash Equivalents (Year End) | $11.8 million | $2.7 million |
| Working Capital | $17.4 million | $12.0 million |
| Accumulated Deficit | $(189.9) million | $(155.0) million |
| Long-Term Debt | $0 | $17.4 million |
Note: The company had no commercial product sales; revenue was derived entirely from government contracts and grants.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 24% ($6.5 million) compared to 2009. This was primarily due to reduced activity in the Protexia® program (contract expired Dec 31, 2010) and a temporary suspension of Valortim® activities following a clinical hold.
- Asset Impairment: The company recognized a non-cash impairment charge of approximately $4.6 million related to the shutdown of Canadian operations and the expiration of the Protexia® contract.
- Debt Elimination: In November 2010, the company converted approximately $17.0 million of its 10% convertible notes into common stock, eliminating all long-term debt by year-end.
- Derivative Liability Increase: A loss of approximately $5.5 million was recorded due to the change in fair value of derivative instruments (warrants), driven by an increase in the company's stock price.
- Bad Debt Expense: The company recorded approximately $2.9 million in bad debt expense related to an invoice from a government customer for work performed prior to a contract novation.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management believes current cash resources and expected government contract receipts will fund operations through at least the end of 2011. The company anticipates increased revenue under the Valortim® contract in 2011 following the lifting of a partial clinical hold in December 2010. Future funding for Valortim® beyond September 2011 remains uncertain.
Unusual Items
- Protexia® Wind-down: Incurred $0.6 million in severance/termination benefits in Q4 2010, with an estimated additional $0.1 million in 2011.
- Convertible Note Conversion: Incurred $2.8 million in expenses related to the call and conversion of 10% convertible notes, including $1.1 million in cash incentive offers.
Risks and Contingencies
- Government Funding Dependence: Substantially all revenue is contingent on U.S. government contracts. Budget constraints or policy changes could lead to contract non-renewal or termination.
- Delisting Risk: The company received notice from NYSE Amex regarding non-compliance with stockholders' equity requirements. A compliance plan was submitted to regain compliance by January 2012; failure to do so could result in delisting.
- Litigation: Ongoing litigation against Siga Technologies regarding rights to the drug candidate SIGA-246. Trial concluded in January 2011; outcome is uncertain.
- Regulatory Approval: Products rely on the FDA "Animal Rule" for approval, which involves significant time and cost with no guarantee of success.
Investor Verification Checklist
- Contract Renewals: Verify the status of the Valortim® contract extension beyond September 2011 and the potential for new funding for the rBChE (AES) program.
- Delisting Status: Monitor progress on the NYSE Amex compliance plan to ensure continued listing of common stock.
- Litigation Outcome: Review the final judgment in the Siga Technologies lawsuit for potential monetary damages or licensing rights.
- Cash Burn Rate: Assess whether the $11.8 million cash balance is sufficient to sustain operations through 2011 given the history of negative operating cash flows.
- Derivative Liability: Monitor the fair value of outstanding warrants, as stock price volatility significantly impacts reported net loss.